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Abstract 
Objectives: An LC-MS/MS method was developed for simultaneous quantitation of 
tacrolimus, sirolimus and everolimus in whole blood, and compared to HPLC-UV and 
immunoassay methods. 
Design and Methods: Blood (0.1 mL) was analysed following solid-phase extraction 
and chromatographic resolution using a C18 column (45 °C) and mobile phase of 
methanol/40 mM ammonium acetate/glacial acetic acid (83/17/0.1) at 200 µl/min, 
with positive electrospray ionisation and multiple reaction monitoring. 
Results: Intra- and inter-day imprecision and inaccuracy were ≤12.2% over a 1.5-40 
µg/L calibration range. An external quality assurance program confirmed acceptable 
inaccuracy and imprecision of the LC-MS/MS method, but highlighted problems with 
immunoassay quantitation, particularly for everolimus, showing a >30% bias in FPIA 
everolimus concentrations measured in pooled patient samples versus spiked drug-
free whole blood. 
Conclusions: LC-MS/MS provides significant accuracy and precision advantages 
compared to HPLC and immunoassays. Discrepancies in everolimus concentrations 
measured by the Seradyn FPIA immunoassay require further investigation. 
Key words: LC-MS/MS, immunoassays, sirolimus, tacrolimus, everolimus 
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Introduction 
The structurally related macrolides tacrolimus, sirolimus and everolimus are 
increasingly used for maintenance immunosuppression following solid organ 
transplantation, typically in combination with a steroid and mycophenolic acid. All of 
these agents have narrow therapeutic indices and, as a result of highly variable inter-
subject pharmacokinetics, require therapeutic drug monitoring to individualise dosage 
based on trough target concentration ranges of 5-20 µg/L for tacrolimus, 3-8 µg/L for 
everolimus, and 4-12 or 12-20 µg/L for sirolimus with or without concomitant 
cyclosporine therapy [1]. The routine monitoring of whole blood immunosuppressant 
concentrations has traditionally involved immunoassay methods, which provide 
sensitivity at the low µg/L concentrations that are targeted in transplant recipients. 
However, the performance of immunoassay methods can be significantly 
compromised by matrix effects as well as cross reactivity between closely related 
compounds. 
Significant immunoassay cross reactivity (up to 140%) has been reported between 
sirolimus and everolimus [2-4], and although they are unlikely to be administered 
simultaneously to patients, it is possible that transplant recipients may be swapped 
from one to the other, in which case significant immunoassay bias may be introduced 
during the first few weeks of monitoring while the ceased drug is eliminated from the 
circulation [2, 4]. This is especially important if swapping from sirolimus to 
everolimus, given the long half-life of sirolimus (≈ 60 h), making dosage 
individualisation for everolimus particularly difficult. Immunoassay cross-reactivity 
has also been demonstrated between tacrolimus and its 31-O-desmethyl (186%) and 
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15-O-desmethly (97%) metabolites [5], sirolimus and its hydroxy (44-50%) and 41-
O-desmethyl (86-127%) metabolites [6], and everolimus and some of its minor 
metabolites [7]. In addition, haematocrit, and other matrix effects have also been 
shown to significantly affect immunoassay quantitation of sirolimus and tacrolimus 
[8-10]. Both cross reactivity and matrix effects are thought to contribute to a mean 10-
20% positive bias of many immunoassays compared to more specific 
chromatographic methods [2, 6, 8, 11-13], although bias may be significantly higher 
at low immunosuppressant concentrations [11, 14], or in samples with low 
haematocrit [8, 10]. 
Advances in mass spectrometry instruments over the last decade have lead to 
increased utilisation of high performance liquid chromatography coupled to tandem 
mass spectrometry (LC-MS/MS) as a means of providing assays with increased 
specificity and sensitivity, with the aim of improving the quality of patient care [15]. 
Several LC-MS/MS methods have been published for the quantitation of individual 
[16-20] or multiple immunosuppressants [21-23] in whole blood. Our laboratory 
initially introduced a previously published LC-MS/MS method for the analysis of 
sirolimus [20], which has subsequently been modified to also allow the additional 
simultaneous quantitation of tacrolimus and everolimus. Performance of the modified 
LC-MS/MS method was compared with the methods previously used in our 
laboratory, HPLC with UV detection for sirolimus [24], and commercially available 
immunoassays for tacrolimus and everolimus, using specimens received as part of an 
international proficiency testing program (www.bioanalytics.co.uk). 
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Methods 
Chemicals and Reagents 
Tacrolimus was purchased from LC Laboratories (MA, USA). Sirolimus and 32-
desmethoxyrapamycin were provided by Wyeth Research (NJ, USA). Everolimus was 
provided by Novartis Pharmaceuticals (Basel, Switzerland), and ascomycin was 
purchased from Sigma Chemical Company (NSW, Australia). Methanol, acetonitrile, 
heptane, isopropanol and zinc sulphate were all of analytical grade. Stock solutions of 
drugs (10 mg/L) and internal standards (100 mg/L) were prepared in methanol and 
diluted in 50:50 methanol:water to 100 µg/L (sirolimus, tacrolimus and everolimus), 
900 µg/L ascomycin and 300 µg/L 32-desmethoxyrapamycin. Calibration standards 
containing sirolimus, tacrolimus and everolimus were prepared by dilutions of the 
methanol:water solutions in lysed whole blood to attain concentrations of 1.5, 3, 10, 
20, and 40 µg/L. Precipitating solution consisted of 0.15 mM zinc sulphate solution in 
70% acetonitrile with or without (blank) internal standards (32-desmethoxyrapamycin 
30 µg/L, ascomycin 10 µg/L). 
Sample Preparation 
To 100 µL blood (calibrator or proficiency testing sample) was added 300 µL 
precipitating solution, followed by mixing and centrifugation (13200 g, 5 min). The 
sample supernatants were then loaded onto preconditioned solid-phase extraction 
(SPE) cartridges (100 mg Sep Pak C18, Waters, MA, USA), washed with 3 mL of 
water, 1 mL 20% methanol in water and 1 mL heptane, and eluted with 1 mL 50/50 
isopropanol/heptane [20]. The eluent was dried using an evacuated centrifuge at 45 
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°C. Samples were then reconstituted in 100 µL of 50/50 methanol/water prior to LC-
MS/MS analysis. 
LC-MS/MS Analysis 
A sample volume of 40 µL was injected into an Agilent 1100 Series HPLC system 
(Agilent Technologies, CA, USA), with a Sunfire® C18 column (50 mm x 2.1 mm, 5 
µm particle size, Waters, MA, USA) and a mobile phase consisting of methanol/40 
mM acetate (83/17 v/v) containing acetic acid (85 µL/L) pumped at a flow rate of 0.2 
mL/min at 45 ºC. Analysis time was 3.5 min. Detection was carried out with an API 
2000 MS/MS instrument (ABSciex, VIC, Australia) operating in positive mode 
electrospray ionisation with multiple reaction monitoring (MRM), based on a 
previous method for the quantitation of sirolimus [20]. Compound-independent 
instrument parameters included: curtain gas flow (30 AU), CAD gas (2 AU), ion 
spray voltage (5500 V), turbo temperature (400 °C), nebuliser gas (40 AU), and 
heater gas (20 AU). Compound-dependent parameters were optimised for each 
individual precursor→product ion mass transition, and included declustering potential 
(30 V), focusing potential (400 V), entrance potential (10 V) for all compounds, and 
collision energies (17, 28, 21, 20 and 26 V), collision cell entrance potentials (38, 28, 
34, 30 and 27 V) and collision cell exit potentials (21, 26, 26, 30 and 20 V) for 
tacrolimus, sirolimus, everolimus, 32-desmethoxyrapamycin and ascomycin, 
respectively. Nitrogen was used as the collision gas. Peak area ratios obtained from 
the MRMs for tacrolimus (m/z 821.5→768.6), sirolimus (m/z 931.7→864.5), 
everolimus (m/z 975.7→908.6), 32-desmethoxyrapamycin (m/z 901.7→834.5) and 
ascomycin (m/z 809.3→756.4) were used for quantification. Standard curves (1.5, 3, 
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10, 20 and 40 µg/L) were constructed using weighted (1/x) linear least-squares 
regression. 
Evaluation of Extraction Efficiency and Matrix Effects 
The efficiency of the SPE step was determined by comparing analyte peak areas of 
spiked whole blood taken through the entire extraction and dry-down process, with 
those from blank blood spiked after SPE extraction but prior to dry-down. The overall 
efficiency was determined using extracted blank blood spiked during the final 
reconstitution step. All samples were spiked to the equivalent of a 3 µg/L calibrator 
sample and reconstituted in 100 µL 50/50 methanol/water (or 100 µL of spiking 
solution in methanol/water, as appropriate). The isopropanol/heptane eluting solution 
was also spiked directly with the analytes of interest and evaporated to dryness using 
the evacuated centrifuge or a stream of nitrogen, at both room temperature or 45 ºC. 
The effect of temperature on compound stability was also evaluated by incubating 
spiking solution (100 µL) at 45 ºC for 2 h prior to LC-MS/MS analysis. Matrix effects 
were assessed by the quantitative post-extraction method [25], using blood samples 
received for monitoring of cardiovascular or anticonvulsant agents from patients not 
on immunosuppressant therapy. A total of 10 blood samples from different 
individuals were extracted, dried and reconstituted in spiking solution (equivalent to 3 
µg/L), and compared to direct injection of the spiking solution. 
Inaccuracy and Imprecision 
Linearity was assessed by analysis of whole blood standards comprising known 
quantities of sirolimus, tacrolimus and everolimus over a concentration range (1.5 to 
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40 µg/L). Intra-day inaccuracy and imprecision were determined with multiple 
replicates (n=7) at the lowest and highest measured concentrations. Inter-day 
inaccuracy and imprecision were evaluated over twenty separate calibration curves 
prepared and analysed on separate days by four different analysts. 
Assay performance was further evaluated by reviewing the laboratory’s performance 
in the UK NEQAS International Proficiency Testing Scheme 
(www.bioanalytics.co.uk) over a 12 month period. This was compared to the 
laboratory’s previous 12 months performance using HPLC-UV detection of sirolimus, 
the MEIA IMx immunoassay for tacrolimus (Abbott Laboratories, IL, USA), and 
FPIA TDx immunoassay for everolimus (Seradyn Inc., IN, USA). 
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Results 
An example chromatogram of a whole blood calibrator is shown in Fig. 1. The assay 
was linear over the range 1.5 – 40 µg/L with r2 values ≥0.993 and mean (s.d.) 
regression equations (n=9) for sirolimus of y = 0.0208(0.0016)x + 0.0043(0.0073), 
tacrolimus of y = 0.0180(0.0011)x +0.0108(0.0025) and everolimus of y = 
0.0231(0.0019)x +0.0010(0.0036). Inter- and intra-day performance of calibrators is 
summarised in Table 1, showing both inaccuracy and imprecision < 12.5 % for 
concentrations from 1.5 to 40 µg/L. Only minor matrix-associated ion suppression 
was observed (< 20%), which did not affect assay consistency as described by 
coefficients of variation < 6.5% (Table 2) and overall assay performance (Table 1). 
The lower limit of quantitation (LLOQ) for sirolimus, tacrolimus and everolimus was 
set as the lowest concentration tested, 1.5 µg/L, with inter-day coefficients of 
variation of 10.3-12.2% and total errors of approximately ± 20%. The upper limit of 
quantitation was set at 40 µg/L, as this was the highest concentration tested. 
Mean (s.d.) overall recoveries were 52.1 (3.6) %, 40.4 (7.0) %, 56.8 (6.6)%, 42.7 (8.3) 
% and 44.5 (7.0)% for sirolimus, tacrolimus, everolimus, 32-desmethoxyrapamycin 
and ascomycin, respectively. However, the SPE efficiency was 92.3 (6.5)%, 110.0 
(19.2) %, 98.3 (11.4) %, 104.1 (20.3) % and 106.0 (16.8)%, respectively, indicating 
that the majority of compound was lost during the dry down procedure. This was most 
likely due to adsorption to the glass tubes, as loss during the dry-down procedure was 
significantly attenuated by the presence of whole blood extract (data not shown). 
Temperature had no effect on overall recoveries (data not shown), and since 
sensitivity was not a limiting factor, the issue of adsorption was not pursued further. 
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Performance of the LC-MS/MS method in the UK NEQAS international proficiency 
testing program is shown in Fig. 2. The previous 12 months’ performance using 
conventional HPLC or immunoassay methods is shown in Fig. 3. For each 
proficiency testing sample, the NEQAS reports the performance of the individual 
participating laboratory and also provides mean results for all participants categorised 
by analytical method type. For our comparisons, the programme’s LC-MS/MS group 
method mean was used as the expected analyte concentration. For all three 
immunosuppressants, variability was decreased using the LC-MS/MS assay, with 
improvements in r2 and Sy.x values compared to the older analytical methods (Figs. 2 
and 3). When using the LC-MS/MS or HPLC-UV assays there was no statistically 
significant difference in mean bias between proficiency testing samples that were 
spiked blood samples or pooled blood samples from patients administered 
immunosuppressants (Table 3). However, for both tacrolimus and everolimus 
immunoassay methods, the mean bias for pooled patient blood samples was 
significantly greater than that for spiked blood samples (Table 3). To confirm that the 
observation of bias with the FPIA everolimus immunoassay was not due to error in 
our internal laboratory procedures, we compared the performance of our laboratory’s 
LC-MS/MS and FPIA everolimus methods using only the spiked NEQAS proficiency 
testing samples, and with repeated measures analysis of variance found no difference 
between the everolimus concentrations measured by our LC-MS/MS method and the 
corresponding weighed-in target spiked concentrations, but a statistically significant 
difference (p<0.01) between everolimus concentrations measured by our FPIA 
method versus the target spiked concentrations. In addition, we also compared the 
NEQAS FPIA group method means for everolimus concentrations to the NEQAS LC-
MS/MS group method means, again confirming significant overestimation in pooled 
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patient samples compared to spiked samples (mean (95% CI) bias of 24.0 (16.2, 
31.8)% versus –8.3 (-12.1, -4.5)%, respectively, P<0.0001 by unpaired t-test). 
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Discussion 
Several LC-MS/MS positive electrospray ionisation methods have been published 
describing the simultaneous analysis of immunosuppressants in whole blood [17, 21-
23, 26-29]. To avoid matrix effects and maximise assay specificity these methods 
have variously employed off-line liquid-liquid extraction [26], SPE extraction [27, 
28] or more recently on-line sample clean-up [17, 21-23, 29]. We have used off-line 
SPE to both concentrate samples and provide added matrix clean-up, based on a 
published LC-MS/MS method for the quantitation of sirolimus in whole blood [20]. 
Like us, the authors reported close to 100% analyte recovery after SPE, but did not 
report the effect of the SPE eluent dry-down step on final recoveries. Using SPE the 
method’s overall performance was also within published guidelines [30], achieving a 
LLOQ of 1.5 µg/L based on an initial 100 µL sample volume, which compares well 
with other methods that similarly report LLOQs for sirolimus, tacrolimus and 
everolimus between 1 and 2.5 µg/L [17, 22, 23]. The calculation of 95% and 90% 
confidence intervals for inter-day reproducibility at clinically relevant concentrations 
indicates that for all 3 immunosuppressants ≤5% of results would be expected to 
differ by more than 15% from a target value of 10 µg/L, whilst at 3 µg/L ≤10% of 
sirolimus results would differ by more than 20% from the target value, ≤5% of 
tacrolimus results would differ by more than 15% and ≤10% of everolimus results 
would differ by more than 15%. The LC-MS/MS method also performed well in the 
international proficiency testing programme, showing linear correlations with r2 
values > 0.97 for all three analytes, and 95% confidence intervals for mean bias 
within a total range of 20-24 percentage points (Table 3). 
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Given the previously reported influence of matrix and metabolite cross-reactivity on 
immunoassays, we investigated whether our performance in the proficiency testing 
program had improved compared to the 12 months before introduction of the LC-
MS/MS assay. In particular, we separately compared our performance with NEQAS 
samples that were spiked blank blood to those that were pooled patient specimens. As 
expected, LC-MS/MS performed better than HPLC-UV with respect to variability in 
sirolimus quantitation, most likely reflecting the poorer sensitivity of the HPLC-UV 
assay [24]. However, there was no difference in overall accuracy between the two 
methods, reflecting the specificity of chromatographic methods in general. Similarly, 
there was no difference in relative performance between spiked and pooled patient 
samples. 
The tacrolimus MEIA IMx assay performed relatively well compared to the NEQAS 
LC-MS/MS group mean concentrations, showing a mean 9.1% overestimation in 
pooled patients samples (which contain both parent drug and metabolites) and 
practically no bias (mean of –2.7%) in spiked samples (Table 3). Previous studies 
have reported a positive mean bias (9.9-43.0%) for the tacrolimus MEIA IMx assay 
compared to chromatographic methods [10, 13, 14, 31]. The degree of overestimation 
varies depending on transplant organ and the range of tacrolimus concentrations, and 
has been attributed primarily to interference by low haematocrit and albumin 
concentrations [9, 10], and, to a lesser extent, cross reactivity with metabolites [5]. 
The small but significant difference in bias between spiked and pooled patient 
specimens observed in this study is likely to also reflect matrix effects and metabolite 
cross reactivity in the tacrolimus MEIA IMx assay. No significant difference in bias 
was observed between spiked and pooled patient samples analysed by our LC-MS/MS 
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method, although there was a small overall positive bias (12.1%) compared to the 
proficiency testing group mean, possibly reflecting a small bias in our in-house LC-
MS/MS calibration standards, and highlighting the potential benefits of using 
commercially prepared calibration standards. 
Again there was no difference between pooled and spiked specimens when measuring 
everolimus concentrations with the LC-MS/MS method, and there was no significant 
trend for over or underestimation. However, there was a concerning significant 
(p<0.0001) difference in performance of the FPIA TDx everolimus assay between 
NEQAS spiked and patient samples (Table 3). Whilst the assay appeared to perform 
relatively well for pooled patient specimens, it significantly underestimated 
everolimus concentrations in spiked whole blood (Table 3), resulting in a relative 
mean positive bias of 30.3% for patient versus spiked samples. The reason for such a 
large discrepancy is not clear, but can not be attributed to differences in calibration, as 
the same manufacturer-supplied material was used throughout. In addition, a similar 
significant bias between spiked samples and pooled patient samples was also 
observed when comparing the NEQAS method means for all laboratories using FPIA 
versus chromatography. Interestingly, the statistically significant underestimation of 
everolimus concentrations by our FPIA method compared to the target NEQAS 
spiked values suggests a calibration problem with the FPIA assay, which was not 
observed with our LC-MS/MS assay. Whether this involves a NEQAS-specific matrix 
effect that contributes to underestimation of spiked proficiency testing samples by 
FPIA or a problem with the commercial FPIA calibrators that may mask possible 
metabolite cross-reactivity [7] in patient specimens, remains to be determined. 
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Salm et al [12] have previously reported a discrepancy between the stated target 
everolimus concentrations of the FPIA immunoassay calibrators/controls and the 
corresponding concentrations measured by their LC-MS/MS method, which used in-
house calibrators. However, in their study the differences in calibration were thought 
to have contributed to overestimation of everolimus concentrations by the FPIA TDx 
method versus LC-MS/MS. Other groups have also reported an average 25% 
overestimation of everolimus concentrations by the FPIA TDx method versus 
chromatographic methods [2, 11]. The large discrepancy observed in our study 
between pooled patient samples and spiked samples raises the possibility that the true 
magnitude of metabolite cross reactivity and/or matrix effects in the FPIA assay may 
be greater than is suggested using the assay’s current calibration method. Regardless 
of the mechanisms, such a large discrepancy warrants further investigation to ensure 
the suitability of proficiency testing samples and that clinical care of transplant 
patients receiving everolimus is not compromised by variability in analytical methods. 
In conclusion, LC-MS/MS had significant reproducibility and accuracy advantages 
compared to both immunoassay and conventional HPLC-UV methods for the 
quantitation of tacrolimus, everolimus and sirolimus concentrations in whole blood. 
The use of UK NEQAS proficiency testing samples comprising both spiked whole 
blood samples and pooled samples from patients administered immunosuppressant 
therapy, has highlighted potential inaccuracy problems with both immunoassays. In 
particular, the >30% bias in everolimus concentrations of pooled versus spiked 
NEQAS specimens measured using the Seradyn TDx immunoassay requires further 
investigation to determine its cause and potential clinical impact. 
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Figure Legends 
Figure 1. Example chromatogram of a whole blood calibration standard (20 µg/L) 
showing the elution times of the five analytes. 
Figure 2. Correlation between sirolimus, tacrolimus and everolimus LC-MS/MS UK 
NEQAS Group Mean concentrations (µg/L) and LC-MS/MS concentrations (µg/L) 
measured in our laboratory for proficiency testing specimens received over a 12 
month period. Closed symbols indicate specimens prepared from pooled patient 
samples, open symbols indicate specimens prepared from spiked drug-free whole 
blood. 
Figure 3. Correlation between sirolimus, tacrolimus and everolimus LC-MS/MS UK 
NEQAS Group Mean concentrations (µg/L) and corresponding HPLC-UV, MEIA 
IMx and FPIA TDx concentrations (µg/L) measured in our laboratory for proficiency 
testing specimens received over a 12 month period. Closed symbols indicate 
specimens prepared from pooled patient samples, open symbols indicate specimens 
prepared from spiked drug-free whole blood. 
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Table 1. Intra- (n=8) and inter-day (n=20) imprecision, inaccuracy and measurement 
uncertainty (mean ± 1.96 x s.d.) of the LC-MS/MS assay determined for whole blood 
calibrator samples. 
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Table 2. Evaluation of matrix effects using extracted drug-free blood (n=10 different 
donors) reconstituted in spiking solution compared with direct injection of spiking 
solution. 
 Inaccuracy (%) CV (%) 
SIROLIMUS 6.7 3.6 
TACROLIMUS -16.0 2.4 
EVEROLIMUS -18.9 6.3 
32-DESMETHOXYRAPAMYCIN -16.7 2.8 
ASCOMYCIN -12.4 2.9 
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Table 3. Comparison of mean (95% CI) percentage bias in quantitation of sirolimus, 
tacrolimus or everolimus concentrations in NEQAS proficiency testing specimens 
prepared from pooled whole blood from patients administered immunosuppressants (n 
= 10-13) versus drug free human blood spiked only with parent drug of interest (n = 
20-27). Bias was determined as (laboratory concentration - NEQAS LC-MS/MS 





-8.6 (-15.4, -1.8) % 
-1.2 (-6.6, 4.3) % 
HPLC-UV 
-2.2 (-28.6, 24.3) % 





9.1 (2.2, 16.0) % 
13.9 (9.1, 18.6) % 
MEIA IMx 
14.8 (-0.6, 30.3) % * 





-6.3 (-17.9, 5.2) % 
-1.7 (-4.1, 0.7) % 
FPIA TDx 
13.2 (4.2, 22.1) % *** 
-17.1 (-23.2, -11.0) % 
• p < 0.05 versus spiked, *** p < 0.0001 versus spiked by unpaired t-test. 
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Fig 1. 
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Fig 2. 
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Fig 3. 
 
